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Summary
One Health is an interdisciplinary collaboration that aims at mitigating risks 
to human health arising from microorganisms present in non-human animal 
species, which have the potential to be transmitted and cause disease in 
humans. Different degrees of scientific collaboration and sectoral integration 
are needed for different types of zoonotic diseases, depending on the health and 
associated economic gains that can be expected from a One Health approach. 
Indeed, mitigating zoonotic risks related to emerging diseases with pandemic 
potential is different from mitigating risks related to endemic zoonotic diseases 
like brucellosis. Likewise, management of brucellosis at the wildlife–livestock 
interface in wildlife conservation areas is in essence different from mitigating 
transmission of a given Brucella species within its preferential host species, 
which in turn is different from mitigating the spillover of a given Brucella species 
to non-preferential host species, humans included. Brucellosis economic models 
often oversimplify and/or wrongly assess transmission between reservoir hosts 
and spillover hosts. Moreover, they may not properly value non-market outcomes, 
such as avoidance of human disease, consumer confidence and conservation 
biology issues. As a result, uncertainty is such that the economic predictions 
of these models can be questionable. Therefore, understanding the infection 
biology of Brucella species is a prerequisite. This paper reviews and highlights 
important features of the infection biology of Brucella species and the changing 
epidemiology of brucellosis that need to be integrated into a true One Health 
perspective of brucellosis.
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Introduction
One Health is an interdisciplinary collaboration that 
aims at mitigating risks to human health arising from 
microorganisms (potentially pathogens) present in non-
human animal species. Changes in the burden of human 
diseases, their spatial distribution, and types of pathogens 
of concern, have arisen largely due to changing human 
activities that are occurring as a result of increasing 
populations and economic development. Interaction of 
humans and livestock with wildlife exposes them to the risk 
of pathogen spillover. Livestock may become intermediate 
or amplifier hosts from which pathogens can spill over into 
humans or humans can be infected either directly from 
wildlife or via vectors (1). It has been estimated that 58% 
of human pathogens are zoonotic, and 13% are emerging, 
of which 73% are zoonotic (2). Additionally, 26% of human 
pathogens infect both domestic and wild animals (3).
Such information helped the One Health concept to gain 
momentum, putting the emphasis on emerging zoonoses, 
particularly those viral emerging zoonoses with pandemic 
potential, such as Ebola, severe acute respiratory syndrome 
(SARS) and H1N1 influenza (4). Brucellosis, however, is 
a bacterial disease, usually enzootic, with, under certain 
epidemiological situations, an increasing prevalence in 
livestock and/or wildlife, leading to an increased incidence 
in humans at a local or regional level. We understand 
intuitively that the measures needed to mitigate the burden 
of zoonoses with pandemic potential are different from 
those needed to mitigate the risks from brucellosis, an 
infection whose hallmark is chronicity. Likewise, it seems 
obvious that the degree of cross-sector integration needed 
(e.g. between public health, veterinary public health and 
environment health) will vary too (5). In the case of an 
emerging zoonosis with pandemic potential, for example, 
collaboration between the animal and public health sectors 
is vital, because early detection in the animal reservoir is 
paramount in order to avoid transmission to humans. 
However, cooperative action between these two sectors is 
less urgent in cases of enzootic brucellosis, which does not 
spread quickly, and often displays a patchy distribution of 
high or low prevalence at both local and regional levels (6).
It is worth noting that, in some developed countries, 
brucellosis has been eradicated and has thus become 
exotic or alien. From an economic point of view, it is of 
the utmost importance to achieve and to keep ‘brucellosis-
free’ status. Indeed, if this status is lost, national and 
international veterinary regulations impose restrictions on 
animal movements and trade, which can result in huge 
economic losses (7). In such situations, brucellosis is seen 
as an economic disease of livestock, and management is a 
matter for national Veterinary Services. Measures focus on 
recovering ‘brucellosis-free’ status and the disease is not 
viewed from a One Health perspective.
Regardless of the type of zoonosis, there is a common 
need to decipher and understand the infection biology of 
pathogens in order to be able to design and implement valid 
mitigation strategies. In 2013 the World Organisation for 
Animal Health (OIE) published an issue of the Scientific 
and Technical Review which looked at brucellosis from the 
One Health perspective (web.oie.int/boutique/). This paper 
will not summarise this information, but is rather aiming 
to highlight new research findings related to the infection 
biology of Brucella spp. and to the changing epidemiology 
of brucellosis, which are crucial for defining a true One 
Health perspective of brucellosis.
Brucellae are Gram-negative, facultative intracellular 
bacteria that can infect many mammalian species, including 
humans. Ten species are recognised within the genus 
Brucella:
– a group composed of the six ‘classical’ Brucella species, 
some of which include different biovars: Brucella abortus 
(biovars 1, 2, 3, 4, 5, 6, 7, 9), B. melitensis (biovars 1, 
2, 3), B. suis (biovars 1, 2, 3, 4, 5), B. ovis, B. canis and 
B. neotomae
– a group represented by the ‘new’ recently described 
species: B. ceti and B. pinnipedialis, B. microti and B. inopinata.
 Worldwide, the main pathogenic species for livestock are:
– B. abortus (all biovars), responsible for bovine brucellosis
– B. melitensis (all biovars), the main aetiological agent of 
brucellosis in both small ruminants and humans
– B. suis (biovars 1, 2 and 3), responsible for swine 
brucellosis
– B. ovis, causing brucellosis in sheep.
The capacity of Brucella spp. to survive and replicate within 
host macrophages plays a critical role in their ability to 
produce disease in their mammalian hosts (8).
Insights into the taxonomy and 
evolution of Brucella spp. gained 
from whole-genome sequencing
The first Brucella genome sequences were released in the 
early 2000s, and their analysis confirmed the previously 
held ideas concerning just how closely related they were 
(9, 10, 11). With the explosion in genomic sequencing, 
unanalysed draft sequences are being added to the databases 
on a regular basis, however, much of this data has yet to 
be analysed in the context of Brucella biology. Analysis of 
42 genomes, including the type strains of all the recognised 
Brucella spp. and, when relevant, biovars, as well as all of 
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(B. inopinata BO1 and B. inopinata-like BO2), as well as 
a group of strains isolated from Australian rodents in the 
1960s that had originally been misclassified as B. suis biovar 
3 (12).
Comparison of the genomes of Brucella spp. with those of 
their closest phylogenetic relatives, Ochrobactrum anthropi 
and Ochrobactrum intermedium, provides some insight into 
how Brucella has evolved from being a soil bacterium, to 
an opportunistic pathogen, then to an intracellular stealth 
pathogen that causes a chronic infection. Ochrobactrum 
strains have a much larger genome than Brucella spp. 
(O. anthropi: 5.2 Mb, 5,100 genes; O. intermedium: 4.7 Mb, 
4,600 genes; Brucella spp.: 3.1–3.4 Mb, 3,200–3,700 genes), 
showing that there has been considerable genome reduction, 
or parallel evolution. However, the road to virulence has 
also required the acquisition of new characteristics that are 
the recently described unclassified strains, has clarified the 
evolutionary relationships in the genus (Fig. 1). The strains 
can be separated into two main groups that we will call the 
‘classical’ and the ‘atypical’ Brucella spp. Work is ongoing 
by the Subcommittee on the Taxonomy of Brucella (of the 
International Committee on Systemics of Prokaryotes) to 
define standards for the genus.
The ‘classical’ Brucella spp. are a group that includes the 
Brucella species that were described first (B. melitensis, 
B. abortus, B. suis, B. canis, B. neotomae, B. ovis). This group 
also includes the marine mammal isolates (B. ceti and 
B. pinnepedialis) and B. microti. Despite the appellation 
‘classical’, these strains, which were the result of an 
explosive radiation event, are in fact the most recent in 
evolutionary terms (12). The ‘atypical’ strains include 
the two recent strains isolated from unusual human cases 
Fig. 1 
Phylogenetic analysis of 42 Brucella genomes 
The maximum-parsimony tree is based on 193,760 single nucleotide polymorphisms (SNPs). The early-diverging Brucella strains are clearly 
differentiated from the classic Brucella strains, with 2,672 SNPs unique to the classic Brucella strains and 1,172 SNPs unique to the outer clade (strains 
NF2653, 83/13, BO1, and BO2). The tree was rooted with Ochrobactrum spp. as outgroups. All branches have 100% support unless otherwise noted
524 Rev. sci. tech. Off. int. Epiz., 33 (2)
not found in Ochrobactrum, and the Brucella core genome 
(classical and atypical) has genes encoding 170 proteins that 
are not found in either of the two Ochrobactrum genomes, 
and a further 249 genes are unique to the classical strains. 
Many of these genes are found in genomic islands that may 
or may not be present, depending on the strain. A subset 
of these Brucella-specific genes are involved in intracellular 
survival and multiplication and allow the bacterium to 
obtain metal ions, such as iron, nickel and magnesium, 
which are important co-factors for many enzymes, but 
are not freely available within the host (12). The clearest 
virulence factor is the VirB type IV secretion system (T4SS); 
here, the operons encoding T4SS dedicated to conjugation 
found in Ochrobactrum have been lost in Brucella spp. and 
replaced by a virulence-dedicated system. In addition, some 
of the recently identified substrates of the T4SS are not 
found in Ochrobactrum spp. (12).
Modification of the lipopolysaccharide (LPS) was also an 
important step in the evolution of Brucella spp. to become 
pathogens of mammalian hosts; interestingly, strain BO2, 
which shows low levels of virulence in cells, has a rhamnose-
based O-polysaccharide (OPS) antigen associated with the 
LPS which is similar to that of Ochrobactrum, while all other 
strains have a perosamine-based OPS antigen (13). Loss of 
resistance to strong acid is another consequence of genome 
reduction that is occurring in most of the classical Brucella 
spp.; this may indicate a change in transmission route 
from oral infection to vertical transmission in utero (12). 
One of the key aspects of the biology of Brucella spp. that 
genomic sequencing has not yet been able to fully explain 
is the genetic basis of the host specificity of the different 
Brucella spp. Based on genomic analysis to date, it is clear 
that the preference of different Brucella spp. for a host 
is not based on a specific gene or pathogenicity island, 
but may rather be related to small genomic changes that 
affect expression or function of shared genomic content. 
It is likely that minor differences in the physiology of 
the different host species of Brucella spp. also play a role 
in establishing the host specificity and preference of the 
different species.
Insights into  
the pathology and clinical 
manifestations of brucellosis
Diagnostic capabilities play a central role in implementing 
control measures based on the One Health concept (6), 
since prevention of zoonotic infections and potential 
human disease requires an accurate diagnosis both of 
animal and human infections. Recognition of clinical 
and pathological signs or symptoms and lesions that are 
compatible with brucellosis is a critical initial step towards 
a sound differential diagnosis.
The outcome of infection is highly dependent on the 
species of Brucella and the mammalian host involved (14). 
While Brucella spp. are not host-specific, they tend to be 
host-restricted, with variable ability to infect and cause 
disease in non-preferred hosts, including humans. Here, the 
focus is on disease associated with Brucella species with the 
highest zoonotic potential, namely B. melitensis, B. abortus, 
and B. suis (14, 15). Other Brucella spp. that are pathogenic 
for humans, such as B. canis, B. ceti and B. pinnipedialis, 
will also be briefly mentioned. Although domestic animal 
species are the most important source for human infections, 
either due to occupational risk or consumption of contaminated 
food (15), the potential role of wildlife for maintaining the 
disease will be briefly discussed. Although B. ovis is a major 
reproductive pathogen for sheep, it will not be included in 
this review since it does not cause human disease (14).
Brucella melitensis is by far the most important 
Brucella spp. for humans (14, 15). Goats are very 
susceptible to infection, and they are considered the 
primary host for B. melitensis (16). Infection usually occurs 
through the oral route, and the most important clinical 
manifestation in goats is abortion at variable stages of 
gestation, which is associated with lesions in the placenta 
and fetus (17). In bucks, infection is often associated with 
genital lesions (e.g. inflammation of the testis, epididymis, 
seminal vesicle, and deferent duct). Chronic infections are 
often associated with articular inflammation and hygroma 
formation (16). Although not all infected goats abort, they 
usually shed the pathogen in the environment, which 
poses a high risk of infection to other susceptible animal 
species that share the same environment (e.g. cattle and 
sheep), as well as for animal handlers (17). Experimental 
infection of goats with B. abortus demonstrated that the 
organism localises in the mammary gland (18), which is 
similar to what is observed in experimental infection of 
cows with B. abortus, resulting in shedding of the pathogen 
in the milk (14).
While bovine infections with B. melitensis are quite common 
in cattle raised in close contact with infected goats, cattle 
are the primary host for B. abortus (6). Brucella suis (mostly 
biovars 1, 2 and 3) also infects cattle, but such infections are 
usually not associated with clinical signs (19). Pathogenesis 
of B. abortus in cattle has been thoroughly reviewed (20). 
The most important clinical manifestations of brucellosis in 
cattle are abortion during the last third of the gestation and the 
birth of weak calves, which is associated with high neonatal 
mortality rates. These clinical signs are often accompanied 
by fibrinous and necrotising placentitis (14), which is 
associated with the tropism of B. abortus for trophoblastic 
cells, which are highly permissive for intracellular growth 
of the pathogen (20). Infected fetuses often develop 
lesions, particularly fibrinous pleuritis and/or pneumonia 
and fibrinous pericarditis (14). Calves transplacentally 
infected or infected by ingesting contaminated milk usually 
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remain asymptomatic, but they may later abort or give 
birth to infected calves, thus maintaining the disease in the 
herd (21). Infected cows also tend to have reduced milk 
yield, with an increase in the number of somatic cells in 
the milk (18), which is associated with interstitial mastitis 
containing intralesional B. abortus, and shedding of the 
pathogen in the milk (14). In bulls, B. abortus infection may 
be asymptomatic, but it often leads to orchitis, which may 
be associated with epididymitis and seminal vesiculitis. 
Chronic infections may progress to diffuse testicular fibrosis 
and permanent infertility (21).
Pigs are susceptible to B. suis infection, particularly biovars 
1, 2 and 3. Brucellosis in pigs tends to be a more generalised, 
chronic, and bacteraemic disease than brucellosis caused by 
B. abortus in cattle (17). Brucellosis suis infection in pigs is 
associated with abortion, stillbirths, decreased litter size, 
weak piglets, infertility, orchitis and epididymitis in males. 
Spondylitis is common, and it is occasionally associated 
with paralysis. Abscesses may be observed in bones and 
joints (17).
Wildlife may serve as reservoirs for some of the above-
mentioned Brucella spp. For instance, B. suis biovar 4 
naturally infects reindeer/caribou (Rangifer tarandus) 
and moose (Alces alces) in Siberia, Alaska and Canada 
(22). Similarly, B. abortus infection is common in elk 
(Cervus elaphus) and bison (Bison bison) in the Yellowstone 
Conservation Area (YCA) in the United States (23), as is 
B. suis in feral swine (24). Seropositivity to Brucella spp. 
associated with hygromas has been reported in African 
wildebeest (Connochaetes taurinus) and buffalo (Syncerus 
caffer) (25). 
The genus Brucella has markedly expanded in the past few 
years. Among the newly described Brucella species, marine 
isolates, i.e. B. ceti and B. pinnipedialis, have been extensively 
studied and thoroughly reviewed (26, 27). Serological 
evidence of exposure to Brucella spp. has been reported in 
53 marine mammal species, whereas isolation or detection 
of Brucella spp. genomic DNA has been reported in only 
18 such species. These marine isolates are prone to induce 
neurobrucellosis and articular lesions, and they have 
documented potential for infecting humans (26).
Insights into anti-Brucella 
immune responses
Studies of immune responses to Brucella spp. have largely 
been conducted in the mouse model because of the 
availability of reagents and tools, including inbred strains 
of mice. The majority of studies have been conducted with 
B. abortus and B. melitensis.
While Brucella spp. live in professional phagocytes it is 
known that phagocytes can kill Brucella spp. if activated 
by the cytokine interferon-γ (IFN-γ) prior to infection (28). 
Moreover, using gene-deleted mice it has been shown that, 
in the absence of IFN-γ, mice die when challenged with a 
virulent strain of B. abortus (29). This cytokine is produced 
by T lymphocytes. Although the principal producers and 
those most clearly involved in protection are the CD4 T 
cells, other T lymphocyte subpopulations that produce 
IFN-γ include both CD8 T cells and γδ T cells (30), the latter 
of which also produce interleukin-17 (IL-17) (30), another 
proinflammatory cytokine. However, IL-17 does not seem 
to have a protective role since in its absence an increase in 
infection was not found (31). Similarly, while CD8 T cells 
can be cytotoxic (in addition to producing IFN-γ) and such 
cytotoxic cells have been demonstrated to be generated in 
vivo following infection, a clear role for cytotoxic cells is 
not evident (29). Finally, infection of human macrophages 
resulted in decreased major histocompatibility complex 
(MHC) class I molecules on the surface, and thus decreased 
Brucella antigen presentation to CD8 T cells and decreased 
killing (32).
Using wild-type mice it has been shown that infection with 
Brucella spp. results in a decrease in the IFN-γ response after 
the first week of infection (33). The production of IFN-γ 
can be partially rescued by administering recombinant 
interleukin-12 (IL-12) (33), which is made by cells of the 
innate immune system, and activation of those cells via toll-
like receptors (TLRs), particularly TLR2 and TLR4 (34). The 
decrease in the inflammatory response following infection 
is mediated by cytokines most commonly associated with T 
cells, such as interleukin-10 (IL-10) (35) and TGF-β. The 
absence of IL-10 production by CD4 T cells, or the absence 
of its receptor, increases control of the infection and even 
promotes complete clearance (35). Recently, it was shown 
that B cells contribute to the production of these anti-
inflammatory cytokines and thus promote chronic infection, 
in that, in the absence of B cells, but not antibodies, there 
is a rapid reduction in the number of bacteria in the spleen 
between 10 to 14 days post-infection (36).
It has been shown that Brucella spp. actually use B cells 
as a niche in which to survive intracellularly, although 
they do not replicate in this type of cell (37). Despite a 
lack of replication, 10% of cells infected with Brucella spp. 
in vivo are B cells and are responsible for hosting 10% of 
the bacteria in infected mice. Also, Brucella spp. must be 
opsonised (coated) with Brucella-specific IgM antibodies 
and complement components to enter and infect B cells. 
Because antigen-specific IgM is required, infection of B cells 
is unlikely to affect the establishment of infection until after 
the first week. Indeed, B-cell-deficient and B-cell-intact 
mice have comparable infection kinetics until ten days post-
infection (36). The inability to replicate in B cells could 
be due to a lack of the phagosomal acidification needed 
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or lesser extent, the same weaknesses. These include an 
inability to reliably differentiate between antibodies raised 
by vaccination with smooth strains of Brucella spp. (45) and 
antibodies raised by Gram-negative bacteria in possession 
of a highly similar OPS structure (46). It appears that the 
OPS dominates the antibody repertoire to such an extent 
that of the many assays developed with alternative antigens 
none has yet to make it into routine practical use (47).
As a consequence, the fine structural elements within 
the Brucella OPS have recently been revisited to examine 
whether some of the more specific features within it may 
be successfully exploited. It has been known for many 
years that the OPS from Brucella spp. possesses epitopes, 
as defined by mAbs, that are not shared with the OPS from 
Yersinia enterocolitica O:9, which in most other respects has 
an almost identical structure and is the foremost suspect 
for the aetiology of most false-positive serological reactions 
(FPSRs) (48). The main structural features within some 
of these OPS epitopes have been identified and evaluated 
(49), although some that have been hypothesised remain 
elusive (50).
The role and value of specific OPS epitopes in serodiagnosis 
have been investigated. The emphasis has been on 
examining the influence of the occasional α 1-3 linkage 
between the monosaccharide components. This is a key 
feature within the M epitope, even if this ‘antigen’ is not 
evenly distributed between the species of smooth Brucella 
spp. However, recent structural evidence points towards 
the fairly ubiquitous existence of an M-type tetrasaccharide 
epitope at the terminal, extracellular tip of each smooth 
Brucella spp. regardless of the serotype, i.e. A, M or mixed 
A and M (51). Given the preponderance of the OPS as a 
surface antigen, it is feasible to consider that this particular, 
and as far as is known, unique, structure is a site for 
interaction with antibodies and B-cell receptors.
Specific oligosaccharides that match the configuration 
of an M epitope while minimising flanking regions that 
would otherwise create attractive A epitopes have recently 
been developed (52). Such specific, discrete structures 
are not produced in nature. The synthetic M-like 
oligosaccharides have been developed as diagnostic 
antigens in ELISA format and applied to sera from 
cattle that have been infected with B. abortus biovar 1 
(A dominant) strains, sera from uninfected cattle that 
present FPSRs with conventional serological techniques, 
and sera from randomly sampled non-infected cattle. 
The data (J.A. McGiven and D.R. Bundle, manuscript 
submitted) show a highly significant increase in the 
capability of the developed assays to differentiate between 
the infected and FPSR populations – while maintaining 
specificity against the samples from the randomly acquired 
non-infected population – compared to the equivalent data 
derived from ‘native’ Brucella antigens.
for bacterial replication (38), a process that is critical for 
induction of virulence genes such as virB (39).
Some unexpected revelations have been made recently 
regarding both the innate and adaptive immune responses. 
It has been shown that neutrophils have an adverse effect on 
control of the infection, at least in the mouse model. In their 
absence there was more IFN-γ produced and less of the Th2 
cytokine IL-4. Moreover, there was a greater infiltration of 
macrophages and dendritic cells into the spleens of mice 
without neutrophils (40). Similarly surprising was the 
observation that the bacteria in a primary infection were 
controlled in the absence of antibodies as well as in their 
presence (36). However, it may be comforting to know 
that, in secondary challenge studies, antibodies do indeed 
provide a modicum of resistance (31), which supports the 
conventional wisdom.
Novel serodiagnostics  
of brucellosis
Laboratory-based confirmation of disease is a critical tool 
in the battle against brucellosis because there is an absence 
of specific clinical signs in either humans or animals. 
Although culture of Brucella spp. is the definitive diagnosis, 
it is difficult, dangerous and expensive to perform and 
the optimal samples are not always available. Molecular 
methods such as polymerase chain reaction (PCR) are 
proving useful, but direct detection of specific DNA from 
routinely accessible material is insufficiently reliable (41). 
Alternative means of immunodiagnosis, such as the skin 
test and IFN-γ, have still to prove themselves. They present 
not insignificant logistical hurdles and serology remains the 
easier option (42).
The first serological assay, the serum agglutination assay, 
was developed in 1897 and since then a number of 
developments and innovations have taken place. The 
current portfolio of internationally recognised methods 
includes the Rose Bengal test (RBT), the buffered plate 
agglutination test (BPAT), the complement fixation test 
(CFT), the indirect enzyme-linked immunosorbent 
assay (iELISA), the competitive ELISA (cELISA) and the 
fluorescence polarisation assay (FPA) (43). The most recent 
significant innovation was the development of the FPA 
(44), a homogeneous assay based on a purified fluorescein 
isothiocyanate (FITC)-conjugated OPS antigen that can 
be performed relatively quickly and produce quantitative 
data. Like the FPA, all the conventional assays rely upon 
the humoral immunodominance of the OPS to endow them 
with useful diagnostic sensitivity and specificity, as the 
antigens for each of these assays contain this ingredient in 
large amounts. However, each assay possesses, to a greater 
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In addition to resolving the long-standing issue of FPSRs 
in brucellosis testing, the method also has the potential to 
unravel a paradox that exists in the field of vaccination. It 
has long been appreciated that the most protective vaccines 
for brucellosis are smooth strains and that elimination of 
the OPS has a deleterious effect in this regard – although its 
precise role is not well understood (53). It is equally well 
known that vaccination with smooth strains gives rise to 
antibodies that react in and confound conventional assays. 
This completes the paradox. Yet, the application of an 
M-specific diagnostic antigen in combination with a vaccine 
that presents A epitopes only may offer the best of both 
worlds: a protective vaccine that presents OPS allied with 
a DIVA (Differentiating Infected from Vaccinated Animals) 
diagnostic that detects antibodies due to infections with 
Brucella spp. in possession of the M epitope. Only one 
Brucella biovar from the significant smooth species is known 
not to possess this epitope and this, rather intriguingly, is 
B. suis biovar 2 (54).
Somewhat fortuitously (or is it possible that the following 
properties may have some causal association with the 
atypical OPS structure?) B. suis biovar 2 infects but does not 
cause brucellosis in ruminants and is self-limiting (55). It 
also appears to be non-pathogenic for humans (56). Could 
this be an interesting starting point in the search for a new 
generation of brucellosis vaccine(s) for a DIVA strategy?
Brucellosis in terrestrial wildlife
The link between wildlife and many diseases in livestock is 
now well recognised. The long-standing conflict between 
wildlife conservationists, on the one hand, and animal health 
authorities and livestock owners, on the other, is largely based 
on differing strategies implemented to control diseases shared 
by livestock and wildlife. The creation of new interfaces 
between livestock and wildlife due to human activity is the 
most important factor in disease transmission (57).
In the United States, responsibility for wildlife diseases is 
complex and can encompass both state and federal agencies. 
However, in general, transport of wildlife across state 
boundaries requires compliance with regulations for disease 
control programmes for domestic livestock. Brucellosis 
control efforts for cattle in the United States began in 
1934 and formally became an eradication programme 
in 1954. Currently, regulatory efforts rely on serological 
surveillance and removal of seropositive animals, and 
vaccination of prepubescent females deemed to be at risk 
of infection.
At the present time, approximately 6,000 bison in YCA 
and Grand Teton National Park, and approximately 
120,000 elk in the states of Wyoming, Montana and 
Idaho, are the primary concern in regards to persistence 
of B. abortus in a wildlife reservoir. Seroprevalence of 
brucellosis in YCA bison is approximately 50% and data 
suggest that B. abortus can be isolated from approximately 
46% of seropositive bison (58). Seroprevalence in elk varies, 
depending on their association with winter feedgrounds, 
but recent data suggest that the epidemiological features 
of elk brucellosis may be changing as seropositive elk 
are being detected in new areas of the YCA. In regards 
to brucellosis in bison and elk, the origin of infection is 
believed to be infected domestic livestock brought into the 
area more than 100 years ago. Control of disease in elk and 
bison populations is impaired by difficulties in catching 
and handling wildlife, species differences in immune 
responses to vaccines, lack of an efficacious brucellosis 
vaccine that can be effectively delivered, and changes in 
demographics and land management within the YCA. 
Because of the estimated cost and concerns regarding the 
impact of vaccination on behaviour, the National Park 
Service, which has responsibility for management of bison 
in YCA has indicated a desire for a vaccine that is highly 
efficacious in bison and capable of being delivered remotely 
before implementation of a costly vaccination programme. 
Currently, transmission of brucellosis in YCA is prevented 
by spatial and temporal separation between wildlife 
and cattle, and implementation of mandatory calfhood 
and adult vaccination of cattle in high-risk areas. Regardless, 
the persistence of brucellosis in wildlife in this area has led 
to at least 22 cases in which brucellosis has been transmitted 
to livestock in the YCA over the last 11 years, with elk being 
implicated as the source of infection in all instances.
Knowledge of the pathogenesis of brucellosis in bison and 
elk, and immune responses to vaccination, has increased. 
When compared to cattle, naïve bison are more susceptible 
to infection and are more likely to abort after experimental 
challenge during pregnancy (59). Bison also take almost 
twice as long as cattle to clear the attenuated B. abortus 
RB51 vaccine strain from lymphatic tissues (24 and 
12 weeks, respectively) (60, 61). In comparison, the RB51 
vaccine strain has been demonstrated in the lymphatic 
tissues of elk beyond 40 weeks after vaccination (S. Olsen, 
unpublished data). Although bison immune responses to 
brucellosis vaccination are generally comparable to those 
of cattle, peak IFN-γ production to Brucella antigens 
under in vitro conditions is delayed in bison as compared 
to cattle (S. Olsen, unpublished data). Elk demonstrate 
distinct immunological differences after vaccination 
with smooth or rough strains of B. abortus, with immune 
responses that are primarily humoral with poor or limited 
stimulation of cellular immunity (62). This may explain 
why studies with smooth and rough vaccine strains have 
failed to demonstrate adequate protection in elk against 
experimental Brucella challenge (63, 64). Experimental data 
also suggest differences between elk and cattle in the rate of 
abortion after experimental challenge, which may be related 
to immunological differences (S. Olsen, unpublished data). 
An ideal vaccine to address brucellosis in bison and elk 
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in the YCA would induce protective immunity after one 
inoculation, be clinically and environmentally safe, and be 
capable of being remotely administered.
Free-ranging and farmed caribou in Alaska are another 
reservoir for brucellosis, with numerous older reports 
documenting B. suis biovar 4 transmission to humans. 
Serological evidence from as early as 1939 suggested 
brucellosis in Alaska Natives. Alaska reported an average 
of one human case of brucellosis per year from 1958 to 
1980 and a total of seven cases between 1982 and 2010, 
with at least three of the later infections attributed to B. suis 
biovar 4 infections of caribou (65). In Alaska, almost two-
thirds of the estimated 18,000 reindeer in the state are 
found in the Seward Peninsula (66). Since enactment of the 
1937 Reindeer Act, only Alaska Natives or native village 
governments are allowed to own reindeer. A number of 
vaccines have been tried on a small scale and with limited 
success in reindeer. At the present time, except for sporadic 
serological surveillance and very limited use of a killed 
B. suis biovar 4 vaccine, there are no significant regulatory 
activities occurring in relation to brucellosis in farmed 
reindeer in Alaska.
The changing epidemiology  
of brucellosis
The biological nature of Brucella spp. allows persistence in 
various hosts and environments, leading to different modes 
of transmission, e.g.:
– silent transmission in marine wildlife reservoirs, with 
no or minimal signs of the disease in animals which co-
evolved with the bacterium, and with fish or invertebrates 
as a possible source of infection (67)
– spillover from terrestrial wildlife reservoirs to livestock 
and thence to humans (6)
– persistence in soil (68, 69)
– active transmission to rodents (70) or potentially to cold-
blooded hosts (71).
An important shortcoming of brucellosis serology is its 
inability to determine which (smooth) Brucella spp. induce 
antibodies in the animal or human host. Indeed, the 
Brucella OPS carries the immunodominant epitopes that are 
shared by B. abortus, B. melitensis and B. suis and virtually all 
serological tests for detecting anti-OPS antibodies (such as 
the OIE prescribed tests) use B. abortus OPS antigens (72). 
As a consequence, infection in mammalian hosts, including 
humans, with B. abortus, B. melitensis or B. suis, will induce 
the same serological pattern, and antibodies induced by 
these different Brucella species are actually detected by 
the same serological tests. The obvious consequence is 
that sound epidemiological inferences are very difficult to 
make in the presence of seropositivity in multiple species of 
animals. Such shortcomings have recently been extensively 
reviewed and highlighted (6). Nowadays, B. melitensis and 
B. suis infections in cattle are described in different continents 
with different implications in terms of regulatory issues and 
veterinary public health, i.e. transmission of B. melitensis 
and B. suis biovar 1 via milk (6). In the Southern US states, 
there is a high prevalence of B. suis biovar 1 infection in feral 
swine (73). Importantly, feral swine have also been found 
infected with B. abortus, even if they have had no contact 
with cattle for decades (24). The changing epidemiology of 
brucellosis is described below.
Brucella melitensis and Brucella suis  
infections in cattle
Brucella melitensis infection in cattle has been reported in 
France (74) and Spain (75) in areas where B. melitensis was 
found in its preferential hosts, i.e. sheep and goats. The 
occurrence of this in the developing world was further 
illustrated by a recent study in Egypt, in which cattle 
and water buffalo (Bubalus bubalis) kept in a household 
with sheep and goats had 6.32 times the odds of testing 
seropositive for Brucella spp., compared to cattle and water 
buffalo that were not (76). This clearly suggests that cattle 
and water buffalo were infected with B. melitensis. However, 
this could not be confirmed, as there were no attempts to 
isolate the species involved. Recently, another study carried 
out in Egypt has highlighted the need to identify which 
Brucella species are infecting different livestock species 
and to define transmission patterns in order to adopt the 
most suitable control strategies. This study of brucellosis in 
small ruminants in Egypt found strains of both B. abortus 
and B. melitensis, but, in addition, isolates from two cows 
were unexpectedly identified as B. suis (77). Importantly, 
B. suis biovar 1 was isolated from milk in one cow, which 
represents an additional veterinary public health issue.
Brucella suis biovar 1 has been regularly isolated from cattle 
in the United States (19) and is becoming an emerging 
problem in South America (78). Transmission of B. suis 
biovar 1 by feral swine to cattle has become a significant 
regulatory issue, as transmission appears to occur from 
contact when feral swine compete for grain in cattle feeding 
areas. It is worth reiterating that cattle infected with B. suis 
cannot be serologically distinguished from cattle infected 
with B. abortus. In China, an attenuated B. suis biovar 1 
strain named Brucella suis strain 2 is used as an oral vaccine 
in cattle, small ruminants and pigs. Although its efficacy has 
never been demonstrated and its use is not recommended 
by the OIE, it is still widely used in China (79). It has 
recently been isolated from cattle (80). Lastly, B. suis 
biovar 2 has recently been isolated from cattle in Belgium 
(55). Brucella suis biovars 1, 2 and 3 are not considered 
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to be pathogens in cattle (19, 55). Importantly, B. suis 
biovars 1 and 3 are true pathogens for humans, whereas 
B. suis biovar 2 is not (56).
Brucella suis and Brucella abortus  
infections in feral swine
Feral swine (Sus scrofa) are rapidly expanding their ranges 
across the United States, with at least 44 of 50 states 
reporting populations. The rapid expansion into new 
areas has primarily been caused by unregulated human 
transportation of feral swine to establish new populations 
for hunting. In at least 14 states, brucellosis has been 
documented to be present in feral swine, with some 
populations demonstrating high seroprevalence (81). 
Brucellosis in feral swine has been implicated as the cause 
of B. suis infections in humans in a number of cases in the 
United States (82). With the exception of production systems 
which allow contact with feral swine, brucellosis has been 
eliminated in most domestic swine herds. As behaviour 
and topography make complete elimination of feral swine 
unachievable in most areas with established populations, 
regulatory control of feral swine brucellosis is currently 
based on establishing effective separation from domestic 
livestock, and population control by hunting or targeted 
depopulation efforts. Any vaccine considered for field use 
in feral swine would need to be efficacious after remote 
delivery, with delivery via oral baits being ideal. Any vaccine 
for feral swine would also need to be environmentally safe, 
and clinically safe in non-target species.
It should be noted that maintenance of B. abortus has also 
been documented in feral swine, including feral swine that 
had been spatially separated from domestic livestock for 
decades (24). The epidemiological consequences of these 
findings are important. Indeed, B. abortus would have been 
able to perform a ‘host species jump’ and conditions for 
the establishment of a true reservoir of B. abortus in feral 
swine need to be experimentally assessed. Furthermore, 
the mechanisms that enabled this species jump should be 
identified in order to shed light on the mechanisms that 
determine host specificity.
Mixed herds and nomadism
Mixed herding, particularly raising sheep and/or goats along 
with cattle, was reported by many researchers to be a risk 
factor for Brucella transmission between different animal 
species. However, transmission does not occur in both 
directions to the same extent. Indeed, whereas infection of 
sheep and goats with B. abortus is seldom reported (83), 
B. melitensis infection in cattle has regularly been reported. 
Studies performed in sub-Saharan Africa suggest that cattle 
are a significant source of Brucella infection for humans. It is 
not yet known if cattle are mainly infected with B. melitensis, 
as suggested by research in North Africa (84), or with 
B. abortus, as indicated by studies in Zimbabwe (85), or 
with both Brucella species, as recently described in Kenya 
(86). Additionally, the recent occurrence of B. suis infection 
in cattle in Egypt highlights the urgent need to study 
brucellosis in pigs in Africa (77); to date no documented 
report on its isolation in pigs in Africa is available in the 
international literature.
Brucella abortus and Brucella melitensis 
infections in camelids
Camelids represent by far the most important livestock 
species after cattle, small ruminants, pigs and poultry. The 
home ranges of dromedary (Camelus dromedaries) are the 
hot and dry regions of North Africa, Ethiopia, the Near 
East and West-Central Asia, whereas the bactrian camel 
(Camelus bactrianus) occupies the cold deserts of southern 
areas of the former Soviet Union, Mongolia, East-Central 
Asia and China. The habitats of the limeades (genus 
Lama) are the cold heights of Latin America (87). To date, 
brucellosis has not been detected in limeades (78). It is 
worth mentioning that B. abortus and B. melitensis have 
been detected in supramammary lymph nodes in camels 
in Darfur, Western Sudan, and this presents a potential 
hazard to those who consume raw camels’ milk, a common 
practice in nomadic camel owners (88). However, it is not 
known if camelids can sustain a B. melitensis or a B. abortus 
infection without a constant influx of bacteria from their 
true reservoir species (6).  
Brucella ceti and Brucella pinnipedialis 
infections in marine mammals
Recently, two independent studies suggest that hooded 
seals are not the definitive host of B. pinnipedialis (67, 89). 
Indeed, gross pathology associated with B. pinnipedialis 
infection has not been described in seals and vertical 
transmission is not likely to occur, since B. pinnipedialis has 
never been isolated from females of reproductive age. These 
studies point toward the existence of a reservoir of Brucella 
spp. in the aquatic environment, likely in the food web. 
Fish constitute a significant part of the diet of seals. Further 
studies are needed to determine if fish, or other aquatic 
organisms that are part of the diet of seals, can sustain a 
B. pinnipedialis infection.
There have been three reported cases of natural human 
infection associated with Brucella spp. from marine mammals 
(see next section). They were all associated with Brucella 
sequence type (ST) 27, although no contact with marine 
mammals was reported (90). Brucella ST27 has, however, 
been isolated along the Californian coast in a dolphin and 
in a fur seal. Comparative phylogenomics indicates that 
Brucella ST27 (Brucella sp. F5/99 and B. ceti Cudo) cluster 
separately within the marine mammal Brucella spp. group 
(12, 91, 92).
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Altogether, this suggests that there is a reservoir of Brucella 
spp. in the aquatic environment, possibly in fish or other 
aquatic organisms, and that these Brucella spp. may spill 
over to marine mammals and humans.
Zoonotic brucellosis
Despite the high percentage of zoonotic pathogens, 
patients suffering from fever of unknown origin are 
often misdiagnosed and the prevalence of acute bacterial 
zoonoses is underestimated by medical doctors, even in 
endemic regions (93).
Human brucellosis is mainly prevented by controlling the 
health status of livestock, principally through surveillance, 
continuous monitoring and culling of infected animals, 
wildlife exposure control and vaccination. Furthermore, 
import/export regulations for animals and animal products 
from endemic regions as well as food hygiene measures 
counteract human infections.
Vaccination of livestock can be a rapid and relatively 
inexpensive intervention to prevent brucellosis in humans, 
and mass vaccination programmes in small ruminants 
resulted in a significant decline in the incidence of the 
zoonotic disease in the human population in Greece 
(94). A reduction of human brucellosis cases was nearly 
immediately achieved by reducing bovine brucellosis in 
South Korea (95).
Currently, domestic animals, mainly small ruminants, 
play the key role in transmitting the disease to humans 
and, to date, animals are the only known source of 
human infection. The human pathogenic Brucella spp. 
are transmitted within their reservoir species either 
vertically, via the placental route and milk, or horizontally, 
via genital contact or aborted fetuses (96). Humans 
may acquire brucellosis directly by animal contacts or 
indirectly by ingestion of contaminated food products, 
such as unpasteurised milk and cheese or raw meat, or 
by inhalation of aerosolised particles both from animal 
secretions or excreta and from laboratory cultures. Human-
to-human transmission has rarely been reported, so humans 
are generally considered to be incidental or dead-end hosts 
for Brucella (96).
The majority of reported human cases are caused by 
B. melitensis, followed by B. abortus, then B. suis (biovars 
1, 3 and 4). Brucella melitensis (biovars 1 to 3) is the 
causative agent of ovine and caprine brucellosis. However, 
B. melitensis is not restricted to a single host and also infects 
animals such as cattle and other bovidae, camelids and fish 
(97, 98). The severity of clinical signs and symptoms in 
human brucellosis seems to be independent of the species, 
at least, it does not differ between B. abortus and B. melitensis 
infections (99). Furthermore, attenuated live vaccine strains 
used in eradication and control programmes may also cause 
human infections comparable to those caused by the wild-
type field isolates. The comparable impact of the various 
species on human health may be due to the highly similar 
genomes of human pathogenic Brucella spp. (11). Hence, 
the significant differences in host preference might rather 
be explained by gene regulation than by gene configuration 
(69). Classical virulence factors are missing in Brucella 
spp. and metabolic abilities are thought to be responsible 
for pathogenicity, e.g. B. abortus, B. melitensis and B. suis 
encode for a urease that is essential to withstand the low 
pH in the stomach. Brucella ovis lacks this enzyme and 
is not able to cause foodborne infection in humans (96). 
Zoonotic concerns regarding marine mammal strains were 
initially raised following the recovery of a cetacean strain 
of Brucella spp. from a laboratory worker at the Animal 
Health and Veterinary Laboratories Agency at Weybridge in 
the United Kingdom, who had seroconverted after suffering 
from headaches, lassitude and severe sinusitis (100). In 
April 2003, the first report of community-acquired human 
infections with marine-mammal-associated Brucella spp. 
was published. The authors described the identification 
of these strains in two patients with neurobrucellosis and 
intracerebral granulomas. Despite a more than 15-year 
separation, these cases have similarities: both patients 
were from Peru and denied significant exposure to marine 
mammals (101). In 2006, the isolation and characterisation 
of a marine Brucella strain from a New Zealand patient, who 
had not previously been exposed to marine mammals, was 
also reported (102).
Concluding remarks  
and perspectives
Controlling B. abortus infection in cattle and B. melitensis 
infection in small ruminants remains the most effective 
means of mitigating the brucellosis burden in humans. This 
is achieved by standard veterinary public health measures, 
such as vaccination, and was demonstrated in Greece 
in the 1990s (94). Such measures have only rarely been 
assessed from a One Health perspective, with the exception 
of the rough estimation of the benefits to human health of 
livestock vaccination in Mongolia (103). Nowadays, human 
brucellosis remains a major public health problem in the 
Middle East (104) and in China, where its incidence has 
risen dramatically since the beginning of the 21st Century 
(105). Thus, the sound implementation of veterinary 
public health measures remains key for mitigating the risks 
of transmission to humans. To what extent a One Health 
approach will enhance standard veterinary public health 
measures remains to be defined and documented. Indeed, 
from the human health perspective, zoonotic diseases are of 
minor concern when compared to ‘lifestyle diseases’, such 
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as obesity, hypertension, cardio-vascular diseases or cancer, 
unless they have pandemic potential and a huge economic 
impact. Likewise, in terms of the profitability of animal 
production, zoonotic diseases represent only a fraction of 
the global disease burden (5).
When bovine brucellosis is controlled or eradicated, FPSRs 
due to cross-reactivity linked to epitopes associated with 
the LPS emerge as the main regulatory problem, particularly 
in Europe. Until recently, no available serological test 
could discriminate beyond any doubt between FPSRs and 
infection with B. abortus in cattle. All approaches based on 
the detection of antibodies directed towards protein have so 
far failed (106). For the first time in more than two decades, 
the developed assays based on the use of the M epitope 
as antigen have the capability to differentiate between 
infection and FPSRs (J.A. McGiven and D.R. Bundle, 
manuscript submitted). Moreover, the fact that this epitope 
is absent in B. suis biovar 2, that this biovar is self-limiting 
and does not induce pathology in ruminants (56) and that 
it is not zoonotic opens the door for a new generation of 
vaccines, based on B. suis biovar 2, that can be used in a 
DIVA strategy.
Brucella suis infection in pigs is an emerging problem 
in Latin America, with recent reports of human 
brucellosis, particularly in abattoir workers (107). It is 
worth noting that porcine brucellosis is not a reportable 
disease and hence, centrally organised control or eradication 
programmes are not implemented. Nevertheless, brucellosis 
has been eradicated in the vast majority of intensive 
pig production systems in the developed world. It is also 
worth noting that half of the world pig population is 
housed in China, where information on the prevalence of 
brucellosis in pigs is limited (108). However, B. suis biovar 
3 infection in humans has been reported in Guangdong 
Province in China (109), suggesting that brucellosis has not 
been efficiently controlled and that it impacts on human 
health.
The fact that B. abortus, B. melitensis and B. suis are isolated 
from non-preferential hosts more and more frequently 
indicates shortcomings in control programmes and/or 
changes in husbandry practices or wildlife management. 
For example, the isolation of B. suis in cattle may be due 
to the rise in the density of domestic, free-roaming and 
wild pig populations, resulting in enhanced transmission 
possibilities. Transmission is also due to the lack of biosafety 
precautions taken during hunting, as recently described 
in Belgium (55). Such infections are considered spillover 
infections from the true reservoir of Brucella spp. and are 
not sustained persistent infections in non-preferential 
hosts, unless there is a constant flow of Brucella spp. from 
the true reservoir host. As mentioned earlier, maintenance 
of B. abortus has also been documented in feral swine 
populations (24), with one of these populations being 
spatially separated from cattle for decades. If such a species 
jump occurred in YCA with the establishment of a true 
B. abortus reservoir in elk in YCA, this needs to be addressed 
too. In the absence of a safe and efficient vaccine for 
wildlife, the management of brucellosis in wildlife is based 
on a spatio-temporal separation between infected wildlife 
and livestock when infected animals become infectious (i.e. 
when abortion occurs).
Wildlife may become intermediate or amplifier hosts 
from which Brucella spp. can spill over into livestock and 
humans. In France, B. melitensis has been isolated from an 
Alpine ibex (Capra ibex) and has probably spilled over to 
cattle and from cattle to humans (110). In Argentina, B. suis 
has been isolated in armadillos (Chaetophractus villosus), but 
spillover from armadillos to livestock and humans has not 
yet been reported (111).
In the developing world, the recent work done in 
Egypt illustrates the importance of moving away from 
epidemiological inquiries relying solely on serology. 
Indeed, the isolation of B. melitensis and B. suis, in addition 
to B. abortus, in cattle, is of the utmost importance in 
understanding new transmission routes between animal 
species and in designing and implementing sound strategies 
mitigating the risk of human infections (77).
The presence of Brucella spp. in the marine environment, 
particularly in the food web of marine mammals, is also of 
importance. Fish and other aquatic organisms may actually 
be the true reservoirs of marine mammal Brucella spp. 
Given the zoonotic potential of some of these Brucella spp., 
their infection biology needs to be urgently deciphered.
Recent studies have contributed greatly to our understanding 
of the survival strategies of Brucella spp. within hosts and 
other, stressful, environments. However, determinants of 
host specificity have not yet been identified, which remains 
one of the most important research issues. Indeed, this will 
bring important insight into how and why a given host 
species is a reservoir able to sustain an enzootic infection or 
a spillover of a given Brucella spp.
Since brucellosis does not respect borders, be they species 
or geographic, intersectoral collaboration across the fields 
of medicine, veterinary medicine and social science is 
indispensable (112). At the moment, the One Health 
approach is primarily driven by veterinarians, with only 
limited involvement of physicians (112). The relevance 
of real-time syndromic surveillance in doctors’ practices 
or hospitals to uncover zoonotic outbreaks in livestock or 
intentional releases of highly pathogenic agents such as 
Brucella spp. is underestimated (113). Public health may 
benefit from a vivid exchange of information between 
veterinarians and medical doctors and vice versa.
However, the degree of scientific and intersectoral 
collaboration needed for a true One Health approach to 
brucellosis control has yet to be determined. The perspectives 
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« Une seule santé » sur la brucellose
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Résumé
« Une seule santé » se réfère à une collaboration pluridisciplinaire visant à atténuer 
les risques pour la santé publique imputables aux micro-organismes présents 
chez les animaux et transmissibles à l’homme. La collaboration scientifique 
et l’intégration sectorielle requises pour chaque type de maladie zoonotique 
varient en fonction de l’amélioration sanitaire attendue de la démarche « Une 
seule santé » et des bénéfices économiques qui peuvent en résulter. En effet, 
ce n’est pas du tout la même chose d’atténuer les risques zoonotiques liés à des 
maladies émergentes à potentiel pandémique et d’atténuer les risques liés à une 
maladie zoonotique endémique comme la brucellose. De même, les opérations 
de gestion de la brucellose à l’interface entre les animaux sauvages et le bétail 
dans les zones de protection de la faune sauvage sont par essence différentes 
des mesures d’atténuation du risque de transmission d’une espèce donnée de 
Brucella au sein de ses espèces hôtes préférentielles, mesures elles-mêmes 
différentes de celles visant à atténuer le risque de passage d’une espèce donnée 
de Brucella à des espèces d’hôtes incidents, parmi lesquelles l’espèce humaine. 
Les modèles économiques de la brucellose ont tendance à simplifier à outrance, 
voire à surévaluer ou sous-évaluer la transmission entre les hôtes réservoirs 
et les hôtes incidents. En outre, les répercussions autres que celles liées aux 
marchés ne sont pas toujours correctement évaluées ; c’est le cas d’aspects tels 
que l’évitement de la maladie chez l’homme, la confiance des consommateurs et 
la biologie de la conservation. Partant, l’incertitude est telle que les prédictions 
économiques de ces modèles sont sujettes à caution. La connaissance de la 
biologie de l’infection par Brucella spp. s’avère donc une condition préalable. 
Les auteurs examinent et soulignent les caractéristiques essentielles de la 
biologie de l’infection par Brucella spp. ainsi que les changements intervenus 
dans l’épidémiologie de la brucellose qui doivent être pris en compte dans une 
authentique perspective « Une seule santé » sur cette maladie.
Mots-clés
Biologie de l’infection – Brucella spp. – Brucellose – Diagnostic – Épidémiologie – 
Immunité – Résistance – Spécificité d’hôte – Une seule santé – Zoonose.
will be different according to the epidemiological situation, 
and the socio-cultural and economic environments. The 
socio-cultural (113) and economic (103) dimensions of 
brucellosis have been addressed elsewhere. It is worth 
noting that, in the Mongolian study, the authors report 
that only B. melitensis was isolated from human patients. 
This information suggests that human cases related to cattle 
contacts have resulted in B. melitensis infection. Bovines are 
not considered to be maintenance hosts for B. melitensis (6), 
the actual source of B. melitensis is to be found in its reservoir 
species, i.e. small ruminants. Unfortunately, transmission 
between small ruminants and cattle was omitted in the 
model of animal-to-human brucellosis transmission in 
Mongolia (114). This raises question marks about the 
validity of such a model.
Whatever approach is taken to brucellosis control, the 
infection biology of Brucella spp. should not be overlooked 
or wrongly understood. Indeed, this knowledge must 
always be integrated so that confidence in a true One Health 
perspective of brucellosis will be enhanced.
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La búsqueda de una respuesta a la brucelosis  
basada realmente en «Una sola salud»
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C. Baldwin, R.L. Santos, J. McGiven, S. Olsen, I.H. Nymo, A. Larsen,  
S. Al Dahouk & J.J. Letesson
Resumen
La noción de «Una sola salud» presupone una labor de colaboración 
interdisciplinar destinada a reducir los riesgos para la salud humana que plantean 
microorganismos presentes en especies animales capaces de transmitirse 
al hombre y causarle enfermedades. Para diferentes tipos de enfermedades 
zoonóticas se necesitan distintos grados de colaboración científica e integración 
sectorial, dependiendo de los beneficios sanitarios (y beneficios económicos 
conexos) que quepa esperar de los planteamientos de «Una sola salud». En efecto, 
no es lo mismo reducir el riesgo zoonótico derivado de enfermedades emergentes 
potencialmente pandémicas que mitigar riesgos ligados a enfermedades 
zoonóticas endémicas como la brucelosis. Análogamente, combatir la brucelosis 
en la interfaz entre animales salvajes y ganado doméstico en zonas de fauna 
salvaje protegida tiene poco que ver, en esencia, con reducir la transmisión de 
una especie de Brucella dentro de su especie hospedadora preferente, lo que a su 
vez tampoco es lo mismo que contener la extensión de una especie de Brucella a 
anfitriones no preferentes, en particular el ser humano. Los modelos económicos 
de la brucelosis suelen simplificar en exceso y/o evaluar erróneamente la 
transmisión de brucelas de anfitriones que ejercen de reservorio a anfitriones 
no preferentes, que constituyen así un vector de extensión. Además, a veces no 
cifran correctamente los resultados que carecen de valor de mercado, como 
el hecho de evitar contagios humanos, la confianza del consumidor o aspectos 
ligados a la biología de la conservación. Como consecuencia, existe tal nivel de 
incertidumbre que es posible cuestionar las predicciones económicas de dichos 
modelos. Por todo ello, entender la biología de la infección de las especies de 
Brucella es un requisito previo indispensable. Los autores examinan y destacan 
una serie de importantes características de la biología infectiva de las brucelas 
y de su cambiante epidemiología que deben ser integradas en una respuesta a la 
brucelosis que se base realmente en los postulados de «Una sola salud».
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